Stock SPRINT SPRINT BIOSCIENCE AB
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Sprint Bioscience AB

Equities

SPRINT

SE0006343745

Market Closed - Nasdaq Stockholm
Other stock markets
 08:38:28 07/06/2024 pm IST 		5-day change 1st Jan Change
1.3 SEK 0.00% Intraday chart for Sprint Bioscience AB +0.93% -25.07%
08/05 Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/02 Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Sprint Bioscience Licenses the Vada Program to Day One Biopharmaceuticals
CI
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Sprint Bioscience Reports Novel AMLarget Proteins in Ongoing Collaboration
CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Sprint Bioscience Launches NIMA at BIO International
CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021
CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Sprint Bioscience AB Initiates Marketing of an Additional Cancer Drug Program
CI
Sprint Bioscience AB Adds New Cancer Drug Program to its Project Portfolio
CI
Sprint Bioscience AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
Sprint Bioscience Licenses the Cancer Drug Program Vps34 to Deciphera Pharmaceuticals
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SPRINT Stock
  4. News Sprint Bioscience AB
  5. Highlights